Search Login Register

cetuximab (Erbitux) Summary

Description: is an antibody that blocks receptors for epidermal growth factor

Also Known As: Erbitux; C225; IMC C225; IMC-C225; MAb C225

Networked: 2724 relevant articles (449 outcomes, 824 trials/studies) for this Drug

Key Diseases for which cetuximab is Relevant

  1. Colorectal Neoplasms (Colorectal Cancer) : 171 outcomes 293 studies in 1015 results
  2. Neoplasms (Cancer) : 109 outcomes 190 studies in 958 results
  3. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) : 25 outcomes 62 studies in 159 results
  4. Squamous Cell Carcinoma (Epidermoid Carcinoma) : 25 outcomes 49 studies in 227 results
  5. Head and Neck Neoplasms (Head and Neck Cancer) : 23 outcomes 49 studies in 220 results
Show All >>

Drugs Related to cetuximab

  1. irinotecan (Camptosar)
  2. bevacizumab
  3. Epidermal Growth Factor Receptor (EGF Receptor)
  4. oxaliplatin (Eloxatin)
  5. panitumumab (Vectibix)
  6. Fluorouracil (Carac)
  7. cetuximab (Erbitux)
  8. Leucovorin (Folinic Acid)
  9. Cisplatin (Platino)
  10. Monoclonal Antibodies
Show All >>

Therapies Related to cetuximab

  1. Drug Therapy (Chemotherapy)
  2. Radiotherapy
  3. Heterologous Transplantation (Xenotransplantation)
  4. Combination Drug Therapy (Combination Chemotherapy)
  5. Salvage Therapy
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.